Revolutionizing the treatment of bacterial disease.
RTP, North Carolina
Joined May 2013
- Tweets298
- Following367
- Followers1.1K
- Likes316
Locus Biosciences retweeted
Largest ever phage therapy trial shows promise for UTI treatment
Urinary tract–infecting E. coli are increasingly antibiotic resistant but phage therapy offers a compelling alternative: cen.acs.org/pharmaceuticals/… .
Locus Biosciences retweeted
🫁 𝐂𝐑𝐈𝐒𝐏𝐑-𝐞𝐝𝐢𝐭𝐞𝐝 𝐩𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐬 𝐔𝐓𝐈 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 2 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 🫁
US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of CRISPR-edited phage therapy candidate LBP-EC01.
LBP-EC01 is being developed as a novel treatment for uncomplicated urinary tract infections caused by drug-resistant E. coli. The data from the trial were published in The Lancet Infectious Diseases.
Read our summary of the results here:
crisprmedicinenews.com/news/…
#crisprmedicinenews #crisprmedicine #crispr #phagetherapy #UTI #MDRbacteria #AMR #crisprtrial #clinicalnews #geneediting
Locus Biosciences retweeted
NCBiotech portfolio company Locus Bio has announced positive results from the first portion of its Phase 2 trial in drug-resistant UTI, affecting an estimated 150 million people worldwide. Congratulations!
Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-relea…
Locus Biosciences retweeted
With phage therapy, researchers sharpen another arrow in the quiver against antibiotic resistance. trib.al/WGUEpR5
Locus Biosciences retweeted
#CRISPR-based therapies have moved from theory to reality, after the recent landmark #FDA approval of the first such treatment - pharmaphorum provides an overview of the treatment and examines other areas CRISPR tools could make major #medical difference.
pharmaphorum.com/rd/innovati…
Locus Biosciences retweeted
Meet the winners in our 2022 Fast 50 Awards, highlighting the fastest-growing private companies in the Triangle! bizjournals.com/triangle/new…
Locus Biosciences retweeted
The number of people affected by #AntimicrobialResistance in the U.S. grew in the first year of the pandemic. The global burden was already too high. These infections & deaths can be prevented. Read new report on #COVID19 impact on U.S. fight against AR: bit.ly/3AlJxiF
Locus Biosciences retweeted
From IT to #biopharma--learn how Paul Garofolo's career trajectory landed him at the head of @LocusBio, a company revolutionizing the treatment of disease with novel #precisionmedicines. Listen to his interview on the @Biotech2050Pod: bit.ly/3MoJWTO
It was a pleasure to host Paul Garofolo, CEO @LocusBio!
Hear how Paul is leaning on his past experience @Patheon among others to help Locus develop #precisionmedicine to combat #infectiousdisease!
bit.ly/3MoJWTO
#podcast #academia #ecoli @NCState
Locus Biosciences retweeted
more #alliances
~@cronosgroup, @Ginkgo announce achievement of #THCV #equity milestone
~@HealthiPASS partners with @BestNeighborsER
~@CosmosID, @LocusBio announce #microbiome partnership provide long-term #clinicaltrial support
ALT Image Source: https://www.fredhutch.org/en/news/center-news/2020/10/metagenomic-sequencing-covid.html
Locus Biosciences retweeted
It was a pleasure to host Paul Garofolo, CEO @LocusBio!
Hear how Paul is leaning on his past experience @Patheon among others to help Locus develop #precisionmedicine to combat #infectiousdisease!
bit.ly/3MoJWTO
#podcast #academia #ecoli @NCState
Locus Biosciences retweeted
Inside Locus Biosciences' $35M funding: What it means for gene editing startup in RTP #WRALTechWire wraltechwire.com/2022/05/26/…
Locus Biosciences retweeted
J&J-backed @LocusBio closes $35M financing to push #CRISPR-based antibacterial drug into phase 2/3 fiercebiotech.com/biotech/jj…
Locus Biosciences retweeted
The company is developing an E. coli treatment and is on track to grow its employee count to 100 by the end of the year. bizjournals.com/triangle/new…
Locus Biosciences retweeted
RTP's Locus Biosciences closes $35M Series B, investors include J&J and Tencent #WRALTechWire wraltechwire.com/2022/05/18/…
Locus Biosciences retweeted
Recent money on the move saw funding support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
#BiotechCompanies #BioSpace
hubs.ly/Q01bBwmH0
Locus Biosciences retweeted
CRISPR antibacterial company @LocusBio has raised $35M to increase its buying power in the down market buff.ly/3wGGrSW
Locus Biosciences retweeted
Locus Biosciences closed a $35 million Series B round Wednesday morning, featuring some notable names including Artis Ventures, Tencent Holdings, Viking Global Investors, Discovery Innovations and Johnson and Johnson Innovation.
endpts.com/locus-pulls-in-a-…
Locus Biosciences retweeted
“Conduct research today so we will have antibiotics tomorrow” – wise words from @koutterson pharmaphorum.com/r-d/the-ant… #AMR
Locus Biosciences retweeted
Industry Matters: Locus Biosciences enlists CRISPR-enhanced bacteriophages to combat resistant bacteria. scientificinquirer.com/2022/…
Locus Biosciences retweeted
“#AMR has no borders, so a global partnership is very important,” says Walter Fuller, technical officer for antimicrobial resistance at the World Health Organization’s Africa office in Brazzaville. ft.com/content/95f150df-5ce6…